Related Experiment Video
Updated: Jul 29, 2026
08:47
Whole Mount Immunofluorescent Staining of the Neonatal Mouse Retina to Investigate Angiogenesis In vivo
Published on: July 9, 2013
47.4K
Retinal microvascular plasticity in a premature neonate
Y Kandasamy1, L Hartley2, R Smith3
11Department of Neonatology,The Townsville Hospital,Townsville, QLD,Australia.
Journal of Developmental Origins of Health and Disease
|February 1, 2017
Summary
Retinopathy of prematurity (ROP) involves abnormal retinal vessel changes. A case study shows intravitreal VEGF antagonists temporarily improved ROP but vessel tortuosity recurred, indicating retinal plasticity.
Area of Science:
- Ophthalmology
- Neonatology
- Vascular Biology
Background:
- Retinopathy of prematurity (ROP) is a leading cause of blindness in premature infants.
- Abnormal retinal vessel dilation and tortuosity characterize severe ROP.
- Vascular endothelial growth factor (VEGF) signaling pathways are implicated in ROP pathogenesis.
Observation:
- A premature infant (24 weeks gestation, 640 g) developed severe ROP.
- Intravitreal bevacizumab (VEGF antagonist) initially reduced retinal vessel tortuosity and dilation.
- Vessel abnormalities re-emerged four weeks after treatment.
Findings:
- The case demonstrates the dynamic nature of retinal microvascular changes in premature neonates.
- Retinal microvascular plasticity may influence treatment response in ROP.
- VEGF antagonists offer temporary benefits but do not permanently resolve ROP-related vascular changes.
Implications:
- Understanding retinal plasticity is crucial for managing ROP.
- Further research into long-term effects and alternative treatments for ROP is warranted.
- Advances in neonatal care and retinal imaging enable closer observation of ROP progression and vascular dynamics.
